Substance Use Disorders and Co-Occurring Psychiatric Illness

What Patients, Families, and Clinicians Need to Know in 2026

Why This Conversation Matters Now

In 2024, an estimated 48.4 million Americans aged 12 or older — roughly 1 in 6 — met diagnostic criteria for a substance use disorder (SUD) in the past year, according to the Substance Abuse and Mental Health Services Administration’s National Survey on Drug Use and Health.^[1] In the same year, 33.0% of U.S. adults — about 86.6 million people — had either any mental illness or a substance use disorder, and millions had both simultaneously.^[2]

There is encouraging news, too. U.S. drug overdose deaths fell 24.4% between 2023 and 2024 — from 105,007 to 79,384 — the largest single-year decline on record, with synthetic-opioid (largely fentanyl) deaths dropping 35.6%.^[3] That progress is real, but the underlying problem — addiction intertwined with depression, anxiety, trauma, and psychosis — remains one of the defining public-health challenges of our time.

This article, written from a psychiatric clinical perspective and grounded in guidance from the National Institute on Drug Abuse (NIDA), SAMHSA, the American Psychiatric Association, and peer-reviewed medical journals, explains what substance use disorder is, why it so often travels with other psychiatric illness, how the brain is involved, and which treatments actually work.

What Substance Use Disorder Really Is (and Isn’t)

Substance use disorder is a chronic, relapsing brain disease characterized by compulsive substance use despite harmful consequences — not a moral failure or lack of willpower. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) defines SUD across 11 criteria spanning impaired control, social impairment, risky use, and pharmacologic features (tolerance and withdrawal). Severity is graded mild (2–3 criteria), moderate (4–5), or severe (6 or more).

Like diabetes or hypertension, SUD is best understood as a chronic medical condition requiring long-term management.^[4] It can be effectively treated, and many people achieve sustained recovery — in 2024, 23.5 million U.S. adults considered themselves to be in recovery from a substance problem.^[5]

Common Signs of Substance Abuse

Patients and families should consider professional evaluation when they notice:

• Using more of a substance, or for longer, than intended
• Repeated unsuccessful attempts to cut down
• Strong cravings or preoccupation with the substance
• Continued use despite problems at work, school, home, or in relationships
• Giving up important activities; social withdrawal
• Use in physically dangerous situations
• Tolerance (needing more for the same effect) or withdrawal symptoms when stopping
• Mood changes, sleep disruption, unexplained financial or legal problems

Two or more of these features over a 12-month period meets DSM-5-TR criteria and warrants assessment.

The Dual Diagnosis Reality: SUDs Rarely Travel Alone

One of the most clinically important facts in addiction psychiatry is this: substance use disorders and other mental health disorders are the rule, not the exception, when they co-occur. Large epidemiologic studies confirm that roughly a quarter of patients with any past-year psychiatric disorder also have a substance use disorder, and SUD treatment populations show lifetime psychiatric comorbidity of 62%–67%.^[6]

Common Co-Occurring Pairs

Approximately 30%–60% of people seeking SUD treatment also meet criteria for PTSD, and those with comorbid SUD–PTSD have more severe symptoms and poorer treatment outcomes when conditions are treated separately.^[7]

Why Do They Co-Occur? The Shared-Vulnerability Model

Three non-mutually-exclusive pathways explain dual diagnosis:

1. Self-medication. Patients use substances to dampen anxiety, intrusive memories, depression, or psychotic symptoms — providing short-term relief while worsening the underlying disorder.
2. Substance-induced psychiatric illness. Chronic substance use directly alters mood, anxiety, and stress-response circuitry. Heavy alcohol use produces depression; stimulants can induce psychosis; cannabis can precipitate or unmask schizophrenia in vulnerable individuals.
3. Shared neurobiological and genetic vulnerability. A landmark 2023 NIH study identified shared genetic markers underlying multiple substance use disorders and several psychiatric conditions, including elevated risk for depression, suicidal behavior, and psychotic disorders.^[8] The dopaminergic reward system, prefrontal regulatory circuits, and stress-response systems (HPA axis, amygdala) are dysregulated in both addiction and many psychiatric disorders.^[9]

The clinical implication is decisive: both conditions must be treated together, not sequentially.

A Closer Look at the Major Substance Use Disorders

Alcohol Use Disorder (AUD)

AUD is the most prevalent SUD in the United States, affecting 27.9 million Americans aged 12 and older in 2024.^[10] It is strongly bidirectional with depression and anxiety. Three FDA-approved medications anchor pharmacologic care:

• Naltrexone (oral or long-acting injectable) reduces heavy drinking by blocking opioid-mediated reward. The landmark COMBINE trial demonstrated significantly higher abstinence and reduced heavy-drinking risk versus placebo.^[11]
• Acamprosate restores glutamatergic balance and is most useful in maintaining abstinence post-detoxification.^[12]
• Disulfiram produces an aversive reaction to alcohol; effective in motivated patients with supervised administration.

The American Psychiatric Association’s practice guideline recommends naltrexone or acamprosate as first-line treatment for moderate-to-severe AUD.^[13] Despite proven efficacy, only 2.5% of adults with AUD received medications for alcohol use disorder in 2024^[14] — a profound treatment gap.

Opioid Use Disorder (OUD)

OUD remains the deadliest SUD in the U.S. In 2024, opioids were involved in 54,045 overdose deaths, with synthetic opioids (predominantly fentanyl) responsible for 47,735.^[15]

Three medications for opioid use disorder (MOUD) — buprenorphine, methadone, and naltrexone — are the gold standard. In a landmark study of more than 40,000 patients, only buprenorphine or methadone was associated with reduced overdose risk, with a 76% reduction at 3 months and 59% reduction at 12 months versus other treatment pathways including detoxification and behavioral therapy alone.^[16]

Emerging fentanyl-era evidence supports higher buprenorphine doses (greater than 16 mg, up to 24 mg or more) for improved retention and reduced acute-care utilization.^[17] Yet only 17% of Americans with OUD received MOUD in 2024.^[18]

Stimulant Use Disorder

Cocaine and methamphetamine use disorders have no FDA-approved medications. However, contingency management (CM) — a behavioral therapy that provides tangible incentives for verified abstinence — has nearly 40 years of evidence as the most effective intervention available. The 2024 American Society of Addiction Medicine and American Academy of Addiction Psychiatry clinical practice guidelines named CM the frontline treatment for stimulant use disorder.^[19] A Veterans Health Administration study of approximately 3,000 patients found those receiving CM were 41% less likely to die within one year compared to those who did not.^[20]

Cannabis Use Disorder and Psychosis

With marijuana use rising sharply — past-year use grew from 19.0% in 2021 to 22.3% in 2024^[21] — the psychiatric community is increasingly concerned about the cannabis–psychosis link. Yale Medicine reports that regular use of high-potency cannabis quadruples the risk of developing schizophrenia, and a Finnish cohort of 18,000 individuals with cannabis-induced psychosis found nearly 50% later developed schizophrenia.^[22] A 2025 JAMA Network Open analysis estimated that the proportion of Danish schizophrenia cases attributable to cannabis use roughly doubled from approximately 4% in 2000 to 8% in 2010–2016.^[23] The risk is greatest in adolescents and those with family history of psychotic illness.

How Dual Diagnosis Is Properly Treated: Integrated, Not Sequential

For decades, mental-health and addiction services operated in silos — patients were told to “get sober first” before psychiatric care, or vice versa. Modern evidence rejects this approach. NIDA’s Principles of Effective Treatment state that “addicted or drug-abusing individuals with coexisting mental disorders should have both disorders treated in an integrated way.”^[24]

The Pillars of Integrated Care

1. Combined assessment. Every patient presenting with mental illness should be screened for substance use, and vice versa. The Screening, Brief Intervention, and Referral to Treatment (SBIRT) model is evidence-based and feasible in primary care.^[25]
2. One team, one plan. Psychiatrist, addiction medicine specialist, therapist, and case manager work from a unified treatment plan addressing both disorders simultaneously.
3. Medication when indicated — MOUD, MAUD, antidepressants, mood stabilizers, antipsychotics — combined with evidence-based psychotherapy.
4. Evidence-based psychotherapies. Cognitive behavioral therapy (CBT), motivational interviewing (MI), contingency management, dialectical behavior therapy (DBT) for emotion regulation, and trauma-focused therapies (prolonged exposure, EMDR, cognitive processing therapy) for PTSD–SUD comorbidity.
5. Long-term, chronic-care orientation. Recovery is rarely linear; relapse is a clinical event to be managed, not a moral failure.
6. Address social determinants. Housing, employment, legal involvement, and infectious-disease screening (HIV, hepatitis B/C) are integral, not peripheral.^[26]
7. Family and peer support. Twelve-step programs, SMART Recovery, peer recovery specialists, and family education improve long-term outcomes.

Promising Emerging Therapies

• Repetitive transcranial magnetic stimulation (rTMS) has growing evidence for reducing cravings across tobacco, stimulants, opioids, and alcohol.^[27]
• GLP-1 receptor agonists (originally diabetes and obesity drugs) are under active investigation for alcohol and stimulant cravings.
• Psychedelic-assisted therapy (psilocybin, MDMA) is in late-phase trials for alcohol use disorder and PTSD, though not yet FDA-approved.

When to Seek Help — and Where

The most important step is the first one. If you or someone you love is experiencing the warning signs above, contact:

• SAMHSA’s National Helpline: 1-800-662-HELP (4357) — free, confidential, 24/7 treatment referral in English and Spanish
• 988 Suicide & Crisis Lifeline: call or text 988 for any mental health emergency
• Your primary care clinician for screening, brief intervention, and referral
• A psychiatrist or addiction medicine specialist for medication evaluation
• SAMHSA’s treatment locator: findtreatment.gov

The treatment gap remains stark: of the people aged 12 or older classified as needing substance use treatment in 2024, only about 1 in 5 (19.3%) received it.^[28] Closing that gap starts with normalizing the conversation — substance use disorder is a treatable medical illness, often deeply intertwined with other psychiatric conditions, and effective, evidence-based care exists.

Key Takeaways

• 1 in 6 Americans had a substance use disorder in 2024; about 1 in 3 adults had either a mental illness or SUD in the past year.
• Co-occurring mental illness and addiction (dual diagnosis) is the norm, not the exception, in clinical populations.
• Integrated treatment — addressing both disorders together with a unified team — produces the best outcomes.
• Medications save lives: buprenorphine/methadone reduce opioid overdose risk by up to 76%; naltrexone and acamprosate are first-line for alcohol use disorder; contingency management is the most effective treatment for stimulant use disorder.
• U.S. overdose deaths fell 24% in 2024 — progress is possible, but the treatment gap (only ~19% of people who need SUD care receive it) remains the central public-health challenge.

This article is for educational purposes and does not replace individualized medical advice. If you are in crisis, call 911 or call or text 988.

---

References

1. Substance Abuse and Mental Health Services Administration (SAMHSA), 2024 National Survey on Drug Use and Health: Key Findings, July 28, 2025. Link ↩
2. Garnett MF, Miniño AM. Drug Overdose Deaths in the United States, 2023–2024. NCHS Data Brief No. 549. Centers for Disease Control and Prevention, January 2026. Link ↩
3. Recovery Research Institute (Harvard Medical School–affiliated Massachusetts General Hospital). Substance Use Disorder Should Be Evaluated, Managed & Treated Like Other Chronic Health Conditions. Link ↩
4. Crockford D, et al. International quality standards for the treatment of comorbid substance use and mental health disorders. Irish Journal of Psychological Medicine, 2026. Link ↩
5. Sippel LM, et al. Behavioral and neurocognitive factors distinguishing post-traumatic stress comorbidity in substance use disorders. Translational Psychiatry, 2023. Link ↩
6. Logrip ML, Oleata C, Roberto M. Mechanisms of Shared Vulnerability to Post-Traumatic Stress Disorder and Substance Use Disorders. Frontiers in Behavioral Neuroscience, 2020. Link ↩
7. National Institutes of Health. Shared genetic markers underlying substance use disorders identified. ScienceDaily / NIH press release, 2023. Link ↩
8. National Institutes of Health. Shared genetic markers underlying substance use disorders identified. ScienceDaily / NIH press release, 2023. Link ↩
9. National Institute on Alcohol Abuse and Alcoholism (NIAAA). COMBINE Study Data Access. Link ↩
10. Witkiewitz K, et al. Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder. Alcohol Research: Current Reviews, 2022. Link ↩
11. National Institute on Alcohol Abuse and Alcoholism (NIAAA). COMBINE Study Data Access. Link ↩
12. Witkiewitz K, et al. Current and Innovative Medications to Treat Alcohol Use Disorder. Alcohol Research: Current Reviews, 2022. Link ↩
13. American Psychiatric Association. Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Link ↩
14. SAMHSA, 2024 NSDUH Key Findings (op. cit.). Link ↩
15. Garnett MF, Miniño AM. Drug Overdose Deaths in the United States, 2023–2024. NCHS Data Brief No. 549. CDC, January 2026. Link ↩
16. Wakeman SE, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 2020. Link ↩
17. Addiction Policy Forum. Medications to Treat Opioid Addiction Reduce Overdose Fatalities and Improve Patient Outcomes (citing Axeen et al., 2024; Friedmann et al., 2025). Link ↩
18. SAMHSA, 2024 NSDUH Key Findings (op. cit.). Link ↩
19. American Psychological Association Monitor. A time-tested behavioral intervention brings new hope for stimulant use disorder (citing ASAM/AAAP 2024 guidelines and Coughlin et al., American Journal of Psychiatry, 2025), April 2026. Link ↩
20. Coughlin LN et al., American Journal of Psychiatry, 2025 (via APA Monitor, op. cit.). Link ↩
21. SAMHSA, 2024 NSDUH Key Findings (op. cit.). Link ↩
22. Yale School of Medicine. Behind the Smoke: Unmasking the Link Between Cannabis and Schizophrenia, 2024. Link ↩
23. Hjorthøj C, et al. Incident Schizophrenia and Cannabis Use Disorder After Cannabis Legalization. JAMA Network Open, 2025. Link ↩
24. National Institute on Drug Abuse (NIDA). Principles of Drug Addiction Treatment: A Research-Based Guide, 3rd ed. Link ↩
25. SAMHSA. Screening, Brief Intervention, and Referral to Treatment (SBIRT). Link ↩
26. NIDA, Principles of Drug Addiction Treatment (op. cit.). Link ↩
27. Addiction Policy Forum. 10 Key Breakthroughs: Recent Studies Advancing Our Understanding of Addiction, 2025. Link ↩
28. SAMHSA, 2024 NSDUH Key Findings (op. cit.). Link ↩